EX-99.1
2
exhibit1.htm
EX-99.1
EX-99.1
News Release
Contacts:
Integra LifeSciences Holdings Corporation
John B. Henneman, III
Investor Relations:
Executive Vice President
and Chief Financial Officer
(609) 275-0500
jack.henneman@integralife.com
Angela Steinway
(609) 936-2268
angela.steinway@integralife.com
Integra LifeSciences Completes Acquisition of Ascension Orthopedics
PLAINSBORO, NJ, September 26, 2011 (GlobeNewswire) - Integra LifeSciences Holdings Corporation
(Nasdaq:IART) today announced the closing of its previously announced acquisition of Ascension
Orthopedics, Inc. ("Ascension.") Ascension, based in Austin, Texas, develops and distributes a
complementary range of implants for the shoulder, elbow, wrist, hand, foot and ankle.
"The acquisition of Ascension expands our platform in the fast-growing extremities space and
provides us with access to the $600 million shoulder market", said Stuart Essig, Integra's Chief
Executive Officer.
As indicated in the September 12, 2011 press release, this transaction is expected to increase
revenues and dilute earnings per share in both the second half of 2011 and the full year 2012.
Integra will provide more detailed financial guidance regarding the transaction on its third
quarter earnings call next month.
***
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for
surgeons, so they can concentrate on providing the best patient care. Integra offers innovative
solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more
information, please visit
www.integralife.com
.
Additional Information
This news release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that involve risks, uncertainties and reflect Integra's judgment as
of the date of this release. Forward-looking statements include, but are not limited to,
statements concerning expectations for the strategic benefits that this acquisition will provide to
Integra, the effect of the acquisition on our results of operations, including revenue growth and
earnings per share. Such forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from predicted or expected results. Among other things,
Integra's ability to successfully integrate the Ascension business into its own operations could
affect the extent of the strategic benefits that Integra generates from this acquisition, and the
impact of the acquisition on results of operations, including revenue growth and earnings per
share. In addition, the economic, competitive, governmental, technological and other factors
identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form
10-K for the year ended December 31, 2010 and information contained in subsequent filings with the
Securities and Exchange Commission. These forward-looking statements are made only as of the date
hereof, and Integra undertakes no obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or otherwise.

EX - 99 . 1 2 exhibit1 . htm EX - 99 . 1 EX - 99 . 1 News Release Contacts : Integra LifeSciences Holdings Corporation John B . Henneman, III Investor Relations : Executive Vice President and Chief Financial Officer ( 609 ) 275 - 0500 jack.henneman@integralife.com Angela Steinway ( 609 ) 936 - 2268 angela.steinway@integralife.com Integra LifeSciences Completes Acquisition of Ascension Orthopedics PLAINSBORO , NJ , September 26 , 2011 ( GlobeNewswire ) - Integra LifeSciences Holdings Corporation ( Nasdaq : IART ) today announced the closing of its previously announced acquisition of Ascension Orthopedics , Inc . ( " Ascension . " ) Ascension , based in Austin , Texas , develops and distributes a complementary range of implants for the shoulder , elbow , wrist , hand , foot and ankle . " The acquisition of Ascension expands our platform in the fast - growing extremities space and provides us with access to the $ 600 million shoulder market " , said Stuart Essig , Integra 's Chief Executive Officer . As indicated in the September 12 , 2011 press release , this transaction is expected to increase revenues and dilute earnings per share in both the second half of 2011 and the full year 2012 . Integra will provide more detailed financial guidance regarding the transaction on its third quarter earnings call next month . *** Integra LifeSciences , a world leader in medical devices , is dedicated to limiting uncertainty for surgeons , so they can concentrate on providing the best patient care . Integra offers innovative solutions in orthopedics , neurosurgery , spine , reconstructive and general surgery . For more information , please visit www.integralife.com . Additional Information This news release contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks , uncertainties and reflect Integra 's judgment as of the date of this release . Forward - looking statements include , but are not limited to , statements concerning expectations for the strategic benefits that this acquisition will provide to Integra , the effect of the acquisition on our results of operations , including revenue growth and earnings per share . Such forward - looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results . Among other things , Integra 's ability to successfully integrate the Ascension business into its own operations could affect the extent of the strategic benefits that Integra generates from this acquisition , and the impact of the acquisition on results of operations , including revenue growth and earnings per share . In addition , the economic , competitive , governmental , technological and other factors identified under the heading " Risk Factors " included in Item 1A of Integra 's Annual Report on Form 10 - K for the year ended December 31 , 2010 and information contained in subsequent filings with the Securities and Exchange Commission . These forward - looking statements are made only as of the date hereof , and Integra undertakes no obligation to update or revise the forward - looking statements , whether as a result of new information , future events or otherwise .